Impact of the mode of estrogen receptor determination on breast cancer prognosis

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e11609-e11609
Author(s):  
P. Martin ◽  
C. Mazouni ◽  
F. André ◽  
P. Bonnier

e11609 Background: Impact of the mode of estrogen receptor determination on breast cancer prognosis Abstract Background: We examined if the mode of estrogen receptor (ER) determination and expression in primary breast cancer impact on patient's prognosis. Methods: We conducted an analysis on a prospective cohort of 1012 patients treated for stage I-III Breast Cancer at Conception Hospital, Marseille, France between 1984 to 2003. ER was determined according to enzyme immuno-assay (EIA) and immunohistochemistry (IHC). Disease-free and overall survivals were evaluated according to the mode of ER quantification and in function of qualitative or quantitative ER expression. Results: ER was a strong predictor of overall survival in the whole population whatever method used for the status determination (p<0.001); however when stratifying the analysis on ER quantitative expression, ER was still a prognostic indicator in the EIA group for OS (p= 0.004) and DFS (p<0.001), group but not in the IHC group for OS (p=0.58) and DFS (p= 0.195). Conclusions: ER determination in breast cancer is strongly associated with a better prognosis, but the level of influence of ER varies with the assay and ER expression. No significant financial relationships to disclose.

2016 ◽  
Vol 156 (1) ◽  
pp. 149-162 ◽  
Author(s):  
Jieqiong Liu ◽  
Huishan Guo ◽  
Kai Mao ◽  
Kan Zhang ◽  
Heran Deng ◽  
...  

2021 ◽  
Vol 20 ◽  
pp. 153303382110049
Author(s):  
Qing Lv ◽  
Shiming Guan ◽  
Mingjie Zhu ◽  
Hu Huang ◽  
Junqiang Wu ◽  
...  

Fibroblast growth factor receptor 1 (FGFR1) is widely recognized as a key player in mammary carcinogenesis and associated with the prognosis and therapeutic response of breast cancers. With the aim of investigating the correlation between FGFR1 expression and estrogen receptor (ER) and exploring the effect of FGFR1 on endocrine therapy response and ER+ breast cancer prognosis, we examined the FGFR1 protein expression among 184 ER-positive breast cancers by the immunohistochemistry (IHC) method, analyzed the association between FGFR1 expression and disease characters using the Pearson’s chi-square test, and assessed the prognostic role of FGFR1 among breast cancers using Cox regression and Kaplan-Meier analyses. Moreover, in vitro assays were conducted to confirm the correlation between FGFR1 and ER expression and investigate the effect of FGFR1 on tamoxifen (TAM) sensitivity in ER+ breast cancer. The results showed that ER expression was negatively correlated with FGFR1 expression ( P = 0.011, r = -0.221). Moreover, FGFR1 expression was one of the prognostic factors of ER-positive breast cancer (OR = 1.974, 95% CI = 1.043-3.633), and high FGFR1 expression was correlated with decreased breast cancer overall survival. In addition, knocking down FGFR1 inhibited cell proliferation and enhanced TAM sensitivity in TAM-resistant cells. In conclusion, we found that there was a significant negative correlation between FGFR1 and ER levels in ER+ breast cancers, high FGFR1 protein expression was associated with poor breast cancer prognosis, down-regulating FGFR1 could elevate ER expression and is associated with enhanced TAM sensitivity in ER+ breast cancers.


2003 ◽  
Vol 105 (4) ◽  
pp. 542-545 ◽  
Author(s):  
Niels Kroman ◽  
Jan Wohlfahrt ◽  
Henning T. Mouridsen ◽  
Mads Melbye

1993 ◽  
Vol 47 (6-7) ◽  
pp. 256
Author(s):  
F. Di Carlo ◽  
S. Racca ◽  
G. Conti ◽  
M. Tampellini ◽  
F. Pietribiasi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document